CAJ | 학술논문

目的：研究瑞舒伐他汀与曲美他嗪联合治疗冠心病的应用价值。方法选择我院2014年1～6月收治的冠心病患者130例，随机分成研究组（n=65）与对照组（n=65），对照组采用瑞舒伐他汀治疗，研究组则在对照组的基础上加用曲美他嗪进行治疗，比较分析两组临床治疗效果。结果研究组治疗总有效率为96.9%，对照组的治疗总有效率为81.5%，两组治疗总有效率比较差异有统计学意义（P＜0.05）；治疗后，研究组患者的血脂水平与CRP指标均优于对照组（P＜0.05）。结论瑞舒伐他汀与曲美他嗪联合治疗冠心病的应用价值比较高，可以明显改善患者的血脂水平及CRP指标。
목적：연구서서벌타정여곡미타진연합치료관심병적응용개치。방법선택아원2014년1～6월수치적관심병환자130례，수궤분성연구조（n=65）여대조조（n=65），대조조채용서서벌타정치료，연구조칙재대조조적기출상가용곡미타진진행치료，비교분석량조림상치료효과。결과연구조치료총유효솔위96.9%，대조조적치료총유효솔위81.5%，량조치료총유효솔비교차이유통계학의의（P＜0.05）；치료후，연구조환자적혈지수평여CRP지표균우우대조조（P＜0.05）。결론서서벌타정여곡미타진연합치료관심병적응용개치비교고，가이명현개선환자적혈지수평급CRP지표。
Objective To study the rosuvastatin and trimetazidine combined with coronary heart disease treatment application value.Methods 130 patients with coronary heart disease in our hospital from 2014 January to June, were randomly divided into study group (n=65) and control group (n=65), the control group using rosuvastatin treatment, study group on the basis of the control group were treated with trimetazidine, comparative analysis of the therapeutic effect of two groups of clinical.ResultsThe study group the total effective rate was 96.9%, treatment group total effectiveness is 81.5%, the two group total effectiveness comparisons have statistics significance (P<0.05), after treatment, blood lipid levels and CRP index in patients of the study group were signiifcantly better than the control group (P<0.05).Conclusion Rosuvastatin and trimetazidine treatment of coronary heart disease combined with relatively high value,can signiifcantly improve the patient's condition.